These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 32814637)

  • 1. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Becker REN; Meyer AR; Brant A; Reese AC; Biles MJ; Harris KT; Netto G; Matoso A; Hoffman-Censits J; Hahn NM; Choi W; McConkey D; Pierorazio PM; Johnson MH; Schoenberg MP; Kates MR; Baras A; Bivalacqua TJ
    Eur Urol; 2021 Mar; 79(3):364-371. PubMed ID: 32814637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
    Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
    J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
    Ghandour RA; Kusin S; Wong D; Meng X; Singla N; Freifeld Y; Bagrodia A; Margulis V; Sagalowsky A; Lotan Y; Woldu SL
    Urol Oncol; 2020 Sep; 38(9):736.e11-736.e18. PubMed ID: 32684514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective multicenter study of visual response-evaluation by cystoscopy in patients undergoing neoadjuvant chemotherapy for muscle invasive urinary bladder cancer.
    Asad D; Styrke J; Hagsheno M; Johansson M; Huge Y; Svensson J; Pelander S; Lauer J; Netterling H; Aljabery F; Sherif A
    Scand J Urol; 2022 Feb; 56(1):20-26. PubMed ID: 34806518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
    Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
    Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?
    Shen HM; D'Souza AM; Green IF; Pohar KS; Mortazavi A; Zynger DL
    Hum Pathol; 2015 Sep; 46(9):1367-75. PubMed ID: 26232112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer.
    Reese AC; Ball MW; Gandhi N; Gorin MA; Netto GJ; Bivalacqua TJ; Schoenberg MP
    Urology; 2014 Aug; 84(2):358-63. PubMed ID: 25065987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
    Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
    Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
    Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F
    Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.
    van Ginkel N; Hermans TJN; Meijer D; Boormans JL; Voortman J; Mertens L; van Beek SC; Vis AN;
    Int Urol Nephrol; 2022 Dec; 54(12):3145-3152. PubMed ID: 35997906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
    Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
    J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Upstaging After Neoadjuvant Chemotherapy Impacting Eligibility for Vaginal-sparing Cystectomy: Identifying Bladder Cancer Patients Who May Benefit From Interim Imaging.
    Liu WJ; Campbell RA; Michael PD; Wood A; Haywood SC; Eltemamy M; Kaouk J; Campbell SC; Haber GP; Weight CJ; Remer EM; Almassi N
    Urology; 2024 Sep; 191():102-109. PubMed ID: 38908561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience.
    Halabi IE; Husseini ZE; Haibe Y; Charafeddine M; Mukherji D; Temraz S; Bulbul M; Khauli R; Nasr R; Wazzan W; Hajj AE; Geara F; Shamseddine A
    Cancer Treat Res Commun; 2020; 25():100222. PubMed ID: 33080450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.